- $3.95bn
- $3.40bn
- $349.89m
- 90
- 13
- 98
- 73
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 105 | 151 | 207 | 280 | 350 |
Cost of Revenue | |||||
Gross Profit | 84.7 | 122 | 165 | 218 | 273 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 112 | 165 | 275 | 370 | 425 |
Operating Profit | -6.94 | -14.2 | -68.4 | -89.8 | -75.5 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -3.77 | -12.1 | -67.6 | -84.7 | -54.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -5.39 | -9.4 | -64.2 | -90.2 | -61.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -5.39 | -9.4 | -64.2 | -90.2 | -61.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -5.39 | -9.4 | -64.2 | -90.2 | -61.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.051 | -0.09 | -0.611 | -0.837 | -0.545 |
Dividends per Share |